Education
About Us
Working with TipRanks
Follow Us
Open Orphan Plc (GB:HVO)
:HVO
HVO Stock Chart & Stats
Day’s Range― - ―
52-Week Range6.50p - 30.45p
Previous CloseN/A
Volume5.15K
Average Volume (3M)1.99M
Market Cap
£68.70M
Enterprise Value109.63M
Total Cash (Recent Filing)£44.18M
Total Debt (Recent Filing)£12.90M
Price to Earnings (P/E)6.4
Beta-0.07
Next Earnings
Sep 16, 2025EPS EstimateN/A
Last Dividend Ex-Date
May 15, 2025Dividend Yield2%
Share Statistics
EPS (TTM)<0.01
Shares Outstanding687,014,100
10 Day Avg. Volume1,969,928
30 Day Avg. Volume1,992,071
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£28.00Price Target Upside180.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
AcquisitionsThe integration of recent acquisitions CRS and Cryostore is progressing as planned, which is expected to positively impact the company's future revenues.
Revenue TargetsThe company has reiterated its £73m guidance for 2025 and highlighted a healthy opportunity pipeline, suggesting confidence in achieving its revenue targets.
Share Price PotentialThe current share price is seen as an attractive entry point, particularly on a multi-year view, indicating potential for future gains.
Bears Say
Biotech FundingThe continued tight biotech funding environment was highlighted as the primary headwind, versus wider market concerns.
Contract AnnouncementsInvestors will be focused on contract announcements to continue to build revenue cover, which is seen as a key catalyst for the stock.
Revenue Cover RiskThe market remains focused on the need for further conversion of new contracts to build revenue cover as 2025 progresses, indicating a potential risk if not addressed.
Open Orphan Plc News
HVO FAQ
What was Open Orphan Plc’s price range in the past 12 months?
Open Orphan Plc lowest share price was 6.50p and its highest was 30.45p in the past 12 months.
What is Open Orphan Plc’s market cap?
Open Orphan Plc’s market cap is £68.70M.
When is Open Orphan Plc’s upcoming earnings report date?
Open Orphan Plc’s upcoming earnings report date is Sep 16, 2025 which is in 39 days.
How were Open Orphan Plc’s earnings last quarter?
Open Orphan Plc released its earnings results on Apr 10, 2025. The company reported 0.008p earnings per share for the quarter, beating the consensus estimate of N/A by 0.008p.
Is Open Orphan Plc overvalued?
According to Wall Street analysts Open Orphan Plc’s price is currently Undervalued.
Does Open Orphan Plc pay dividends?
Open Orphan Plc pays a Annually dividend of 0.2p which represents an annual dividend yield of 2%. See more information on Open Orphan Plc dividends here
What is Open Orphan Plc’s EPS estimate?
Open Orphan Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Open Orphan Plc have?
Open Orphan Plc has 687,014,100 shares outstanding.
What happened to Open Orphan Plc’s price movement after its last earnings report?
Open Orphan Plc reported an EPS of 0.008p in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.701%.
Which hedge fund is a major shareholder of Open Orphan Plc?
Currently, no hedge funds are holding shares in GB:HVO
Open Orphan Plc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
£28.00 (180.00% Upside)
£28.00 (180.00% Upside)
Insider Transactions
Bought Shares
Worth £157.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.13%
12-Months-Change
Fundamentals
Return on Equity
26.97%
Trailing 12-Months
Asset Growth
6.81%
Trailing 12-Months
Company Description
Open Orphan Plc
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers. The Disease in Motion platform has various potential applications across a range of end users, including big technology, wearables, pharma, and biotech companies. Further, the company provides preclinical and early clinical research services; sales and marketing services; and biometry, data management, and statistics to its various European pharmaceutical clients, as well as drug development consultancy and services, including CMC (chemistry, manufacturing, and controls), and PK and medical writing to a range of European clients. The company was formerly known as Open Orphan Plc and changed its name to hVIVO plc in October 2022. hVIVO plc is headquartered in London, the United Kingdom.
HVO Stock 12 Month Forecast
Average Price Target
28.00p
▲(180.00% Upside)
Technical Analysis
Avacta Group plc
―
Scancell Holdings
―
SkinBioTherapeutics
―
4basebio UK Societas
―
Ondine Biomedical, Inc.
―
Ownership Overview
0.84% Insiders
―
Mutual Funds
― Other Institutional Investors
99.15% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---